AE	Adverse event
BSC	Best supportive care
CEM43	Cumulative equivalent minutes at a temperature of 43 °C
CR	Complete response
CRP	C-reactive protein
CT	Chemotherapy
DFS	Disease-free survival
DMFS	Distant metastasis-free survival
ESHO	European Society of Hyperthermic Oncology
ESMO	European Society of Medical Oncology
HCC	Hepatocellular carcinoma
HNC	Head and neck cancer
HR	Hazards ratio
HT	Hyperthermia
IAEA	International Atomic Energy Agency
IL-6	Interleukin 6
IPCI	Intraperitoneal chemoinfusion
LA	Locally advanced
LACC	Locally advanced cervical cancer
LC	Local control
LDC	Local disease control
LN	Lymph nodes
LPFS	Local progression-free survival
LRC	Loco-regional control
LRFS	Local relapse-free survival
LRRFS	Locoregional recurrence-free survival
mEHT	Modulated electro hyperthermia
NA	Neoadjuvant
NCCN	National Comprehensive Cancer Network
NMA	Network meta-analysis
NPC	Nasopharyngeal carcinoma
NSCLC	Non-small-cell lung cancer
MIBC	Muscle invasive bladder cancer
OR	Odds ratio
ORR	Overall response rate
OS	Overall survival
PCMA	Peritoneal carcinomatosis with malignant ascites
PET	Positron emission tomography
PFS	Progression-free survival
PR	Partial response
RHT	Regional hyperthermia
RR	Relative risk
RCT	Randomised controlled trial
RF	Radiofrequency
RT	Radiotherapy
SCLC	Small-cell lung cancer
SD	Stable disease
STM	Society of Thermal Medicine
STS	Soft tissue sarcoma
SUCRA	Surface under the cumulative ranking curve
TER	Total effective rate
TIL	Tumour-infiltrating lymphocyte
TNFa	Tumour necrosis factor alpha
QoL	Quality of life